The therapeutic activities of orally administered FK482 were compared with those of reference antibiotics against systemic and local infections with a variety of bacteria in mice and rabbits. In systemic infections in mice, oral FK482was almost as effective as oral cefaclor (CCL) and more effective than oral cephalexin (CEX) against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis infections. However, FK482 afforded superior protective activity when given subcutaneously against E. coli infection in mice, and this activity was more potent than that of subcutaneously given CCL. In comparison with CCL, the reason that the in vivo activity of orally given FK482against mouse systemic infections was weaker than had been anticipated from its potent in vitro activity was due to its poor oral absorption in mice. In local infections in rabbits, a species in which FK482 was better absorbed than in mice, FK482 was more effective than CCL, CEXor amoxicillin (AMPC). Against pneumonia induced by S. aureus or Streptococcus pyogenes, FK482was as effective as AMPC and more effective than CCLin reducing the number of viable bacteria in the lungs of infected rabbits. In the oral treatment of experimental ascending pyelonephritis in rabbits, FK482 was superior to CCLand AMPCagainst methicillinresistant S. aureus infection, as effective as AMPCand more effective than CCLagainst Enterococcus faecalis infection, and as effective as cefixime (CFIX) and more effective than CCLand AMPCagainst E. coli infection in reducing the number of viable bacteria in the kidneys and urine.
Werecently began developing FK4822) (Fig. 1) , a new cephem antibiotic for oral use, which combines potent antibacterial activities against Staphylococci and Enterococcusfaecalis with broad spectrum, potent antibacterial and bactericidal activities against Gram-negative bacteria and excellent /3-lactamase stability of ceflxime (CFIX). In this study, the in vivo activities of FK482 were compared with those of cefaclor (CCL), cephalexin (CEX), CFIX and amoxicillin (AMPC). 
Materials and Methods

Antibiotics
The antibiotics used in this study were FK482 and CFIX (Fujisawa Research Laboratories, Osaka, Japan), CCL Clinical isolates of various species of bacteria used were obtained from several hospitals in Japan.
Antibiotic Susceptibility Testing
The MICsof the test antibiotics were determined by the agar dilution method described in our accompanying paper1}.
Protective Effect on Systemic Infections in Mice
Male ICR-strain mice, aged 4 weeks were used in groups of 10. Each challenge organism was cultured overnight on Trypticase soy agar at 37°C and suspended in 5 % bacteriological mucin (Nakarai Chemical Ltd., Kyoto, Japan) at conventional inoculum sizes. A cell suspension of 0.5 ml was injected intraperitoneally and the test antibiotics suspended in 0.5 % methylcellulose solution were given orally or subcutaneously in single doses 1 hour after challenge. The mice were observed for 4 days. The protective effect of the test drugs was expressed in terms of ED50(mg/kg) values which were calculated by the Probit method2). Therapeutic Effect on Experimental Pneumonia in Rabbits Pneumoniawas established in rabbits by the techniques of Kannangaraet al.3\ Japanese white rabbits (male, 1.4~2.2 kg, n=3~18) were anesthetized by intraperitoneal injection of 12 mg of pentobarbital sodium. The ventral portion of the neck was shaved and cleansed with 70% ethanol. The trachea was exposed by a midline vertical incision in the neck, and 15 cm, 20 gauge polyethylene tubing with 22 gauge needle (Igarashi Ika Kogyo Co., Ltd., Tokyo, Japan) was introduced by a single puncture through the upper tracheal rings. The tubing was then introduced into the tracheobrochial tree as far as possible, and the needle was withdrawn with the tubing left in the trachea. 0.5 ml of the bacterial inoculum (Staphylococcus aureus 2548 : 4.2 x l09 cfu, Streptococcus pyogenes S23 : 3.5~5.5 x 108 cfu) was introduced through the trachea. The tubing was then removed, and the incision was closed with metallic skin clips. The animals recovered from the anesthesia soon after procedure and were transferred to their cages. The rabbits were given a single oral dose of 20 mg/kg of the antibiotic 4 hours after challenge and thereafter twice a day on days 2 and 3 for S. aureus infection, and a single dose of 5 mg/kg of the antibiotic twice a day for 3 days starting 24 hours after challenge for S. pyogenes infection.
The rabbits were sacrificed 4 days after challenge, and the lungs were homogenized in physiological saline, appropriately diluted, and the viable cell counts were determined by conventional plating techniques.
Therapeutic Effect on Experimental Pyelonephritis in Rabbits Japanese white rabbits (male, 1.8~2.2 kg, tz=3~ll) were anesthetized by intraperitoneal injection of 12 mg of pentobarbital sodium. The hair of the lower abdomenand left flank was removed with electric clippers, and the operative site cleansed with 70%ethanol. Using sterile instruments, a 3-cm incision was made near the bladder and paralleled to the costal margin. A small segment of the ureter, approximately 2 cmdistal to the bladder, was freed from the surrounding tissues and ligated with silk thread after intraurethral injection of 0.1 or 0.2 ml of the bacterial inoculum ($. aureus 4041 : 3.0 x 104 cfu, E.faecalis 0112: 3.2-4.0 x 104 cfu, Escherichia coli3056: 0.9~3.6 X 103 cfu) witha 26 gauge needle. The peritoneum was closed with silk sutures and the skin incision closed with metal clips. A dose of 20 mg/kg of antibiotic was administered orally twice a day for 3 days from 24 hours after challenge for S. aureus or E. coli infections, or for 2 days from 24 hours after challenge for E. faecalis infection. The animals were killed 4 days after challenge with S. aureus and E. coli, and 3 days after challenge with E. faecalis. The blood, kidneys, liver, bladder tissue and urine in the pelvis and the bladder were aseptically removed. The kidneys were macroscopically examined for abscess and the grade of severity of abscess were expressed as +++, ++? +> db and -. The organs were then homogenized in physiological saline, and appropriately diluted.
The viable cell counts were determined by conventional plating techniques.
Serum Levels and Urinary Excretion in Mice and Rabbits
Male ICR-strain mice aged 4 to 5 weeks were used in groups of 10 and male Japanese white rabbits DEC. 1988 weighing 2.6 to 2.8 kg were used in groups of 5. The antibiotics were given orally in a single dose of 20 mg/kg. At specified intervals after dosing, blood samples were collected by heart puncture from mice and from the ear vein of rabbits, allowed to clot and centrifuged for 15 minutes. For collection of urine, each mousewas housed in a metabolism cage, and the urine samples were collected over a period of 24 hours after dosing. For rabbits, the urine samples were collected through a catheter at 0 to 3 and 3 to 6 hours, and in a metabolism cage at 6 to 24 hours after dosing. The concentrations of the test antibiotics were determined by the disc-plate diffusion technique using Providencia stuartii ATCC43665 as the test organism for FK482, E. coli ATCC391 88 for CFIX and Bacillus subtilis ATCC 6633 for CCL, CEX and AMPC.
Statistical Analyses All statistical analyses were performed with Student's t-test4) for paired differences.
Results
Protective Effect of FK482 and Reference Antibiotics after Oral Dosing on Systemic Infection in Mice The protective effect of orally given FK482 on systemic infections in mice was compared with that of the reference antibiotics (Table 1) . Against S. aureus infection, FK482was almost as effective as CCLand AMPC, and more effective than CEX. Against systemic infections with E. coli, Klebsiella pneumoniae and Proteus mirabilis, FK482was almost as effective as CCLand more effective than CEX, but less effective than CFIX. FK482 had stronger protective effect than AMPCagainst E. coli infection and similar effect to AMPC against P. mirabilis infection. These results show that the protective activity of FK482 after oral dosing in mice did not reflect its potent in vitro activity. Protective Effect of FK482 and CCL after Subcutaneous Dosing on Systemic Infection in Mice The protective activity of FK482 given subcutaneously was compared with that of CCL (Table 2) , Against systemic infection with E. coli, FK482given subcutaneously was about 40 times more effective than that given orally and 8 times more effective than CCLgiven subcutaneously. These results suggest that the protective activity of subcutaneous FK482well reflected its potent in vitro activity, in comparisonwith CCL.
Serum Levels and Urinary Recovery of FK482 and Reference Antibiotics after Oral Dosing in Mice To investigate whythe protective activity of oral FK482against systemic infection in mice did not reflect its potent in vitro activity, the serum levels and urinary recovery of FK482in mice given the drug in oral doses of 20 mg/kg were compared with those of the reference antibiotics. The serum levels and urinary recovery rates of FK482 after oral dosing were the lowest of the test drugs (Fig. 2) . Therefore, it is thought that the unexpectedly weak in vivo activity of FK482was due to its poor absorp- Comparative Serum Levels and Urinary Recovery of FK482 after Oral Dosing in Mice and Rabbits In a preliminary pharmacokinetic study, there were considerable differences in the absorption of orally dosed FK482 among animals. That is, the absorption of FK482 after oral dosing in mice was low, but in rabbits was higher. Fig. 3 shows the serum levels and urinary recovery ofFK482 after an oral dose of 20 mg/kg in mice and rabbits. The peak serum levels of FK482in mice and rabbits were 1.58 and 4.22^g/ml; serum half-lives were 0.4 and 1.1 hours; the area under the serum concentration curve (AUC) (0~oo) were 2.17 and 13.5^g-hour/ml; urinary recoveries (0~24 hours) were 9.8 and 45.8 %; and absolute bioavailabilities were 12.6 and 32.3 %, respectively. These results show that the absorption of FK482was far higher in rabbits than in mice. Wetherefore thought it of interest to investigate the therapeutic efficacy of FK482 against local infections in rabbits.
Therapeutic Efficacy of Orally Dosed FK482 and Reference Antibiotics against Experimental Pneumonia in Rabbits The therapeutic efficacy of FK482 and the reference antibiotics against pneumonia induced by S. aureus 2548 and S. pyogenes S23 in rabbits is shown in Fig. 4 . Against S. aureus pneumonia, the decrease of viable cells in the lungs of FK482-treated rabbits was more marked than in the reference drug-treated animals, although only the FK482-treated group showed a significant difference (P< 0.05) from the non-treated control group and there was no significant difference between the FK482-treated group and the reference drug-treated group. That is, the viable cell counts (log cfu/g) in the lungs after oral treatment were 3.01 ±0.29 for FK482 0=3), 3.99±0.87 for CCL (/i=3), 4.19±0.94 for CEX 0=3), 3.45±0.50 for AMPC(/i=3) and 5.89±0.44 for the non-treated control 0=3). Against S. pyogenes pneumonia, FK482 was as effective as AMPCand more effective than CCLin reducing the number of viable bacteria in the lungs, although there was no significant difference between FK482-treated group and the reference drug-treated group; the viable cell counts were 1.66± 0.65 for FK482 0=5), 2.74±0.28
for CCL 0=8), 1.58±0.22 for AMPC 0=8) and 5.42±0.24 for Vertical bars indicate the SE. a Challenge, 0.9~3.6 x 103 cfu, into left ureter; b treatment, 20 mg/kg, po, twice a day for 3 days from 24 hours after challenge; c observation, 4 days after challenge; d statistical significances refer to Student's t-test for paired differences, significant difference from FK482 (P<0.05). CFIX ; Cefixime, CCL; cefaclor, AMPC; amoxicillin.
number of viable bacteria in the kidneys, urine of the pelvis and in the severity of abscess in the kidneys (Table 3) . Against E. faecalis 0112 pyelonephritis, FK482 (n=6) was almost as active as AMPC (n=6) and more active than CCL (n=6) or the control (n=6) in reducing the number of viable bacteria in the organs and urine, and in the severity of abscess in the kidneys (Table 4) . Against E. coli 3056 pyelonephritis, FK482 (n=5) was almost as effective as CFIX (n=7) and more effective than CCL (n=$\ AMPC(«=3) or the control (n=U) in reducing the number of viable bacteria in the organs and urine. These results suggest that the in vivo activity of FK482against ascending pyelonephritis in rabbits, in which FK482 was better absorbed than in mice, reflected well its potent in vitro activity.
Discussion
In vitro studies on FK482showed that the drug combined potent antibacterial activity against Staphylococci, Streptococci and E. faecalis with the broad spectrum, potent antibacterial activity against Gram-negative bacteria, and excellent stability to /3-lactamases as like as CFIX. We compared the therapeutic efficacies of FK482and commercially available oral /3-lactam antibiotics in experimental infections in animals. In a pharmacokinetic study5), there were considerable differences in the absorption of the compound after oral dosing in different animals. That is, mice and rats showed low absorption (absolute bioavailability: 12.6 and 15.3 %, respectively), rabbits showed moderate absorption (32.3 %) and dogs showed high absorption (72.3 %).
Therefore, we studied the in vivo antibacterial activity of FK482in experimental infections in mice and rabbits. In mouse systemic infections, the protective activities afforded by FK482after oral dosing were almost equal to those of CCL,despite the better in vitro activities of FK482. However, the protective activities of FK482after subcutaneous dosing were superior to those of CCL.These results suggested that the reason for the weaker in vivo activity of orally given FK482against mouse systemic infections was due to its poor absorption after oral dosing in mice. On the other hand, in local infections such as pneumonia and ascending pyelonephritis in rabbits, in which FK482 was better absorbed than in mice, the therapeutic efficacy of FK482after oral dosing reflected well its potent in vitro activity. Therefore, we can say that the clinical efficacy of FK482against infections will depend on its bioavailability after oral dosing in human. FK482 merits further pharmacokinetic and toxicological studies.
